# US 11,897,926 B2 · GIPR-agonist compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,897,926 B2
- Document ID: US11897926B2
- Status: Granted
- Kind: B2
- Application number: 17/573,317
- Filed: 2022-01-11
- Published: 2022-04-28
- Granted: 2024-02-13
- Earliest claimed: 2019-08-01
- Assignees: Eli Lilly and Company
- Applicants: Eli Lilly and Company
- Inventors: Jorge Alsina-Fernandez; Andrea Renee Geiser; Lili Guo; Samantha Grace Lyons Keyser; John Lee; Hongchang Qu; William Christopher Roell
- Web page: https://patentgrep.com/patent/US11897926B2

## CPC

- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- C07K 14/4703: {Inhibitors; Suppressors}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to compounds having activity at the human glucose-dependent insulinotropic polypeptide (GIP) receptor. The present invention also relates to compounds having an extended duration of action at the GIP receptor. Such compounds may be useful in the treatment of diabetes, including type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.

## Claims

### Claim 1

A compound, or a pharmaceutically acceptable salt thereof, wherein the compound is SEQ ID NO:7.

### Claim 2 (depends on 1)

A pharmaceutical composition comprising the compound, or pharmaceutically acceptable salt thereof, of claim 1 and at least one pharmaceutically acceptable carrier, diluent, or excipient.

### Claim 3 (depends on 1)

A method for treating a condition selected from the group consisting of diabetes mellitus, obesity, and metabolic syndrome, in a patient in need thereof, comprising administering to the patient an effective amount of the compound, or pharmaceutically acceptable salt thereof, of claim 1.

### Claim 4 (depends on 2)

A method for treating a condition selected from the group consisting of diabetes mellitus, obesity, and metabolic syndrome, in a patient in need thereof, comprising administering to the patient the pharmaceutical composition of claim 2.